Company intelligence / Profile preview

Ocumeda

Erlen, Switzerland

Ownership: Private
Development stage: Other

Overview

Ocumeda has conducted over 270,000 patient examinations and detected over 45,000 abnormalities early across its network. The company operates Europe's leading tele-ophthalmology platform connecting approximately 300,000 active patients and over 700 optical retail stores with ophthalmologists.[2]

Therapeutic areas: Ophthalmology
Industry: Non-Academic Healthcare

Partnerships

Fielmann Group[1][2]ZEISS Vision Care[2]CSS (largest Swiss health insurance company)[1]BAYER[1]

Beyond the preview

Go deeper on Ocumeda.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ocumeda.

Explore the full profile